SREBF2 and metabolic dysfunction-associated steatotic liver disease: Although differences in the expression of SREBF2 and G6PC did not reach statistical significance, higher SREBF2 expression and lower G6PC expression were observed with increasing NAFLD activity (N2 vs. N0; P = .057 and P = .072, respectively).